Our patient had HCC progression after first-line targeted therapy and ICIs and achieved a better tumor response and longer survival with lenalidomide, and lenalidomide regained efficacy after anti-PD-1 therapy and has not yet progressed. The gene discussed is PDCD1; the disease is neoplasm.